WARBURG PINCUS & CO.
Known title: DirectorCIK: 0000929408
Associated companies
Transaction History
| SHC | ▼ Sell | Open Market | 19,102,952 | $289.8M | 5/13/2026 | View on chart |
| SHC | ▼ Sell | Open Market | 19,102,952 | $289.8M | 5/13/2026 | View on chart |
| SHC | ▼ Sell | Open Market | 15,000,000 | $229.1M | 3/6/2026 | View on chart |
| SHC | ▼ Sell | Open Market | 15,000,000 | $229.1M | 3/6/2026 | View on chart |
| SHC | ▼ Sell | Open Market | 9,720,000 | $158.7M | 12/3/2025 | View on chart |
| SHC | ▼ Sell | Open Market | 9,720,000 | $158.7M | 12/3/2025 | View on chart |
| SHC | ▼ Sell | Open Market | 18,000,000 | $281.7M | 11/10/2025 | View on chart |
| SHC | ▼ Sell | Open Market | 18,000,000 | $281.7M | 11/10/2025 | View on chart |
| SHC | ▼ Sell | Open Market | 12,000,000 | $181.3M | 9/5/2025 | View on chart |
| SHC | ▼ Sell | Open Market | 12,000,000 | $181.3M | 9/5/2025 | View on chart |
| SHC | ▼ Sell | Open Market | 15,000,000 | $225.4M | 9/6/2024 | View on chart |
| SHC | ▼ Sell | Open Market | 15,000,000 | $225.4M | 9/6/2024 | View on chart |
| SHC | ▼ Sell | Open Market | 16,594,363 | $237.4M | 3/4/2024 | View on chart |
| SHC | ▼ Sell | Open Market | 16,594,363 | $237.4M | 3/4/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17
JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17. JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.